BackgroundCheck.run
Search For

Jing J Li, 5746770 Graham Cove Sq, Dulles, VA 20165

Known as:
Jing Jing Li Jing Jingjing Li Jingjing Jing Li Jingjing J Li Jin G Li Jing-Jing Li Jin Gli Li Jing-Jing Shaheen Gandhi
Related to:
Ji Lee

Jing Li Phones & Addresses

46770 Graham Cove Sq, Sterling, VA 20165   

Gainesville, GA   

Herndon, VA   

Germantown, MD   

Gaithersburg, MD   

College Park, MD   

McLean, VA   

Chantilly, VA   

Greenbelt, MD   

Bridgewater, NJ   

Get Report
Control this profile

Mentions for Jing J Li

Career records & work history

Lawyers & Attorneys

Jing Li Photo 1

Jing Li - Lawyer

Licenses:
New York - Currently registered 2012
Education:
The University of Texas School of Law
Jing Li Photo 2

Jing Li - Lawyer

Address:
Xiamen University, International College
Licenses:
New York - Currently registered 2011
Education:
University of Washington
Jing Li Photo 3

Jing Li - Lawyer

ISLN:
1000628314
Admitted:
2009
Jing Li Photo 4

Jing Li - Lawyer

Office:
Kirkland & Ellis International LLP
Specialties:
Corporate
ISLN:
921054526
Admitted:
2007
University:
China University of Political Science and Law, B.A., 2004
Law School:
University of International Business and Economics, LL.M.
Jing Li Photo 5

Jing Li - Lawyer

Office:
LiLaw Inc. - A Law Corporation
Specialties:
Intellectual Property & Technology, Intellectual Property Litigation, Litigation, Intellectual Property Law, Labor & Employment, Solo & Small Firm
ISLN:
915241239
Admitted:
1999
University:
Peking University, B.S.; University of California at Berkeley School of Law; University of North Carolina at Chapel Hill, Ph.D.
Law School:
University of California at Berkeley, Boalt Hall School of Law, JD - Juris Doctor

Medicine Doctors

Jing Li

Specialties:
Internal Medicine
Work:
Winston Salem Baptist Medical Center IM
Medical Ctr Blvd Jane Way Tower 4 7 Floor, Winston Salem, NC 27157
336-7163182 (phone) 336-7165168 (fax)
Education:
Medical School
Hebei Med Univ, Shi Jiazhuang City, Hebei, China
Graduated: 1996
Procedures:
Bone Marrow Biopsy
Languages:
English, Spanish
Description:
Dr. Li graduated from the Hebei Med Univ, Shi Jiazhuang City, Hebei, China in 1996. She works in Winston-Salem, NC and specializes in Internal Medicine. Dr. Li is affiliated with Wake Forest Baptist Medical Center.

Jing F. Li

Specialties:
Family Medicine, Acupuncturist
Work:
Integrative Medical Center
9940 Research Dr STE 100, Irvine, CA 92618
949-5528133 (phone)
Education:
Medical School
Sun Yat Sen Univ of Med Sci, Guangzhou, China (242 21 Pr 1/71)
Graduated: 1982
Conditions:
Gastroesophageal Reflux Disease (GERD), Hypothyroidism, Intervertebral Disc Degeneration, Menopausal and Postmenopausal Disorders, Peripheral Nerve Disorders, Rheumatoid Arthritis, Abnormal Vaginal Bleeding, Acute Bronchitis, Acute Sinusitis, Acute Upper Respiratory Tract Infections, Allergic Rhinitis, Alopecia Areata, Anxiety Phobic Disorders, Aortic Aneurism, Bronchial Asthma, Chronic Fatigue Syndrome, Diabetes Mellitus (DM), Disorders of Lipoid Metabolism, Herpes Simplex, Herpes Zoster, Hypertension (HTN), Insomnia, Migraine Headache, Osteoarthritis, Osteoporosis, Overweight and Obesity, Parkinson's Disease, Psoriasis, Thyroiditis
Languages:
Chinese, English
Description:
Dr. Li graduated from the Sun Yat Sen Univ of Med Sci, Guangzhou, China (242 21 Pr 1/71) in 1982. She works in Irvine, CA and specializes in Family Medicine and Acupuncturist. Dr. Li is affiliated with St Joseph Hospital Of Orange.

Jing Li

Specialties:
Rheumatology
Work:
South Texas Arthritis Care Center
5414 Fredericksburg Rd STE 150, San Antonio, TX 78229
210-6159800 (phone) 210-6159801 (fax)
Languages:
English, Spanish
Description:
Ms. Li works in San Antonio, TX and specializes in Rheumatology.
Jing Li Photo 6

Jing Fang Li

Specialties:
Family Medicine
Pain Medicine
Pain Medicine
Education:
Sun Yat-Sen University (1982)
Jing Li Photo 7

Jing F Li

Specialties:
Family Medicine
General Practice
Education:
University of Illinois at Chicago (1991)

License Records

Jing Li

Licenses:
License #: 0225036895
Category: Real Estate Individual

Jing Li resumes & CV records

Resumes

Jing Li Photo 56

Jing Li - College Park, MD

Work:
University of Maryland 2011 to 2000
Research Assistant University of California - Riverside, CA Sep 2009 to Dec 2010
Research Assistant and Teaching Assistant USDA-Pacific Southwest Research Station Fire Lab - Riverside, CA Jun 2010 to Oct 2010
Internship
Education:
University of Maryland - College Park, MD 2011 to 2014
PhD in Mechanical Engineering University of California - Riverside, CA 2009 to 2010
Master in Mechanical Engineering University of Science and Technology of China - Hefei, China 2005 to 2009
BS in Safety Science Engineering Hong Kong Polytechnic University - Hong Kong 2007 to 2008
CERT in Building Services Engineering
Skills:
materials characterization techniques, CFD modeling, polymer synthesis and thermal analysis,Origin, Tecplot, AutoCAD, Solidworks, labVIEW, FDS,ANSYS, CFAST, Fluent, CHEMKIN, Matlab, FORTRAN, Mathematica, Engineering Equation Solver (EES), C/C++
Jing Li Photo 57

Jing Li - College Park, MD

Work:
Center for Nanophysics and Advanced Materials, University of Maryland Apr 2012 to 2000
Postdoctoral Researcher Center for Nanophysics and Advanced Materials, University of Maryland - College Park, MD Jan 2009 to Feb 2012
Graduate Research Associate Department of Electrical and Computer Engineering, University of Delaware - Newark, DE Aug 2007 to Dec 2008
Graduate Research Assistant
Education:
University of Delaware - Newark, DE 2007 to 2012
Ph.D. in Electrical Engineering University of Delaware - Newark, DE 2007 to 2009
M.S. in Electrical Engineering Wuhan University 2005 to 2007
M.S. in Electrical Engineering Wuhan University 2001 to 2005
B.S. in Electrical Engineering
Skills:
Photolithography, Wet and Dry (Plasma) Etching, Thin Film Deposition (Thermal and E-Beam Evaporation, Sputtering), Wafer Bonding; LASI, AutoCAD; Wire Bonding, Probe Station, Cryogenic Measurement Using Exchange-Gas Cryostats, SEM, Stylus Profilometer; LabView, Origin, Mathematica, MatLab; C
Jing Li Photo 58

Jing Li - Washington, DC

Work:
American Association of Retired Persons (AARP) - Washington, DC Mar 2014 to May 2014
Research Intern Community Academy Public Chapter School - Washington, DC Sep 2013 to Feb 2014
Data Analyst Intern Voice of America (VOA) - Washington, DC Aug 2013 to Nov 2013
Data Analyst Intern (Volunteer)
Education:
The George Washington University - Washington, DC 2012 to 2014
MS in Statistics University of Science and Technology Beijing (USTB) 2008 to 2012
BS in International Economics and Trade
Skills:
SAS Certified Advanced Programmer, SPSS, SQL, R and Microsoft Office

Publications & IP owners

Us Patents

Prediction Of Clinical Response To Il23-Antagonists Using Il23 Pathway Biomarkers

US Patent:
2022037, Nov 24, 2022
Filed:
May 24, 2021
Appl. No.:
17/328816
Inventors:
- Thousand Oaks CA, US
- Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Koustubh Ranade - Gaithersburg MD, US
Katie Streicher - Gaithersburg MD, US
William Rees - Thousand Oaks CA, US
Meina Liang - Gaithersburg MD, US
Raffaella Faggioni - Wilmington DE, US
Jing Li - Wilmington DE, US
Inna Vainshtein - Wilmington DE, US
Jingjing Chen - Gaithersburg MD, US
International Classification:
G01N 33/53
C07K 16/24
A61P 1/04
Abstract:
The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an anti-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Compositions And Methods For Treatment Of Anticancer-Drug Resistant Cancers

US Patent:
2023012, Apr 27, 2023
Filed:
Sep 14, 2022
Appl. No.:
17/944506
Inventors:
- Washington DC, US
JING LI - Arlington VA, US
YILIANG LI - Tianjin, CN
International Classification:
C07F 5/02
A61K 31/69
C07D 311/02
A61P 35/00
Abstract:
Embodiments of the instant disclosure relate to novel methods and compositions for treating tumors resistant to one or more anticancer drugs, such as platinum-based chemotherapeutics.

Compositions And Methods For Treatment Of Platinum-Based Chemotherapeutic Resistant Tumors

US Patent:
2023001, Jan 12, 2023
Filed:
Aug 22, 2022
Appl. No.:
17/892948
Inventors:
- Washington DC, US
Jing LI - Arlington VA, US
Ruiqin WU - Sichuan, CN
Yiliang LI - Hebei, CN
International Classification:
C07C 233/58
C07C 235/74
C07C 235/88
C07C 235/26
A61K 31/16
A61K 31/22
A61K 31/27
Abstract:
Embodiments of the instant disclosure relate to novel methods and compositions for treating tumors resistant to platinum-based chemotherapy. In certain embodiments, methods of treating tumors herein can include administering an effective amount of at least one ursolic acid derivative. In certain embodiments, methods of treating tumors herein can include administering an effective amount of at least one ursolic acid derivative in combination with at least one platinum-based chemotherapeutic separately or in a combination therapy. In some embodiments, methods of treating tumors disclosed herein can include screening and/or selecting a subject suitable for treatment on the basis of SENP1 tumor expression. In other embodiments, methods of treating tumors can include administering a composition disclosed herein to a subject, the composition having a combination of at least one ursolic acid derivative and at least one platinum-based chemotherapeutic.

Cd40L Antagonist And Uses Thereof

US Patent:
2021034, Nov 4, 2021
Filed:
Sep 25, 2019
Appl. No.:
17/279772
Inventors:
- Gaithersburg MD, US
Marius ALBULESCU - Gaithersburg MD, US
Jing LI - Gaithersburg MD, US
Ethan GRANT - Gaithersburg MD, US
Katie STREICHER - Gaithersburg MD, US
Gabor ILLEI - Gaithersburg MD, US
Liangwei WANG - Gaithersburg MD, US
William REES - Gaithersburg MD, US
International Classification:
C07K 14/47
A61P 37/06
C12N 9/26
C12N 9/16
C12N 15/86
Abstract:
A human CD40L-specific Tn3 molecule and therapeutic uses thereof.

Ccl20 As A Predictor Of Clinical Response To Il23-Antagonists

US Patent:
2020026, Aug 20, 2020
Filed:
Dec 16, 2016
Appl. No.:
16/063803
Inventors:
- Thousand Oaks CA, US
- Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Koustubh Ranade - Gaithersburg MD, US
Katie Streicher - Gaithersburg MD, US
William Rees - Thousand Oaks CA, US
Meina Liang - Gaithersburg MD, US
Raffaella Faggioni - Gaithersburg MD, US
Jing Li - Gaithersburg MD, US
Inna Vainshtein - Gaithersburg MD, US
Jinging Chen - Gaithersburg MD, US
International Classification:
C07K 16/24
G01N 33/68
Abstract:
The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).

Prediction Of Clinical Response To Il23-Antagonists Using Il23 Pathway Biomarkers

US Patent:
2018025, Sep 6, 2018
Filed:
Sep 16, 2016
Appl. No.:
15/759330
Inventors:
- Thousand Oaks CA, US
- Gaithersburg MD, US
Brandon Higgs - Gaithersburg MD, US
Koustubh Ranade - Gaithersburg MD, US
Katie Streicher - Gaithersburg MD, US
William Rees - Thousand Oaks CA, US
Meina Liang - Gaithersburg MD, US
Raffaella Faggioni - Gaithersburg MD, US
Jing Li - Gaithersburg MD, US
Inna Vainshtein - Gaithersburg MD, US
Jingjing Chen - Gaithersburg MD, US
International Classification:
G01N 33/68
C07K 16/24
Abstract:
The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.

Isbn (Books And Publications)

Foreign Investment In China

Author:
Jing Li
ISBN #:
0333662415

Possible Relatives

Cynthia M Li  David Li  Dawei Li  Dayu W Li  De Li  Dean Li  Da Li  Jing M Meng  Jing H Lee  Jing Lin 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.